Welcome to our dedicated page for Lexeo Therapeutics news (Ticker: LXEO), a resource for investors and traders seeking the latest updates and insights on Lexeo Therapeutics stock.
Lexeo Therapeutics, Inc. (Nasdaq: LXEO) is a New York City-based, clinical stage genetic medicine company that regularly issues news and updates about its cardiovascular gene therapy programs. The company’s press releases focus on the progress of its lead candidates, LX2006 in Friedreich ataxia (FA) cardiomyopathy and LX2020 in plakophilin-2 (PKP2)–associated arrhythmogenic cardiomyopathy, as well as on regulatory and corporate developments.
Readers following Lexeo news can expect detailed interim clinical data from ongoing Phase I/II trials, including safety findings, measures of cardiac structure and function, arrhythmia burden, and patient-reported outcomes. The company also reports on regulatory interactions, such as FDA feedback on potential accelerated approval pathways and special designations like Breakthrough Therapy, RMAT, Orphan Drug, Rare Pediatric Disease, and Fast Track for LX2006, and Orphan Drug and Fast Track designations for LX2020.
In addition to clinical and regulatory updates, Lexeo uses news releases to announce equity financings, research collaborations, and participation in scientific and investor conferences. Examples include public offerings and private placements of common stock and pre-funded warrants, strategic partnerships to explore non-viral RNA-based therapeutics for genetic cardiac diseases, and research collaborations on targeted cardiac delivery of AAV gene therapy.
For investors, analysts, and others tracking LXEO, this news stream provides insight into Lexeo’s clinical development trajectory, regulatory milestones, financing activities, and scientific collaborations. Revisiting the news page over time allows readers to follow how the company’s genetic medicine programs and corporate strategy evolve based on trial results, FDA interactions, and capital markets events.
Lexeo Therapeutics (Nasdaq: LXEO) will participate in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2026 at 10:00 a.m. ET in Miami, FL.
The presentation will be webcast live via the company's Investors & News & Events page, with a replay available on the Lexeo website after the session.
Lexeo Therapeutics (NASDAQ: LXEO) said members of management will present at two investor conferences in February 2026: a Guggenheim Emerging Outlook: Biotech Summit fireside chat on Feb 12, 2026 at 12:30 p.m. ET in New York and an Oppenheimer Healthcare Life Sciences fireside chat on Feb 26, 2026 at 10:40 a.m. ET (virtual).
Both events will be webcast live and replays will be available under the News & Events tab in the Investors section of the company website.
Lexeo Therapeutics (Nasdaq: LXEO) announced multiple senior leadership appointments and an update to its strategic partnership for cardiac RNA therapeutics on January 27, 2026. Key hires include Narinder Bhalla, MD as Chief Medical Officer, José Manuel Otero, PhD as Chief Operating Officer, and new cardiology development leads Hayes Dansky, MD and Greg Aubert, MD, PhD. Eric Adler, MD will become CEO of Myoventive, a cardiac precision medicines company co-founded by Lexeo and partners to develop a novel non-viral RNA platform for genetic cardiac diseases. The appointments are presented as strengthening late-stage clinical and commercial execution while maintaining discovery and early cardiac development.
Lexeo Therapeutics (NASDAQ: LXEO) reported interim Phase I/II HEROIC-PKP2 data for LX2020 in PKP2-associated arrhythmogenic cardiomyopathy on Jan 12, 2026.
Ten participants dosed (low 2x1013 vg/kg, high 6x1013 vg/kg). LX2020 was generally well tolerated, no clinically significant complement activation, and all LFT elevations resolved with protocol immunosuppression. In biopsies (n=7) mean PKP2 protein increased +93% (low dose) and +162% (high dose). In participants with ≥6 months follow-up (n=8) NSVT improved 22% and PVCs improved 14% in high-dose cohorts. Enrollment complete; 12-month high-dose data due Q4 2026.
Lexeo Therapeutics (NASDAQ: LXEO) announced a research collaboration with Johnson & Johnson on January 8, 2026 to investigate localized cardiac delivery of AAV gene therapy using Impella heart pump technology. The agreement targets preclinical development of a cardiac gene therapy route that concentrates AAV delivery to the heart, with the stated goals of reducing required AAV doses, improving safety, and maximizing transgene expression and clinical efficacy. The program will evaluate cutting‑edge, localized routes of administration combined with direct cardiac unloading to enhance myocardial perfusion.
Lexeo Therapeutics (NASDAQ: LXEO) announced that CEO R. Nolan Townsend will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 7:30 AM PT in San Francisco.
The presentation will be webcast live on the company's investor website under the News & Events tab, and a replay will be posted on the website after the presentation.
Lexeo Therapeutics (Nasdaq: LXEO) will host a virtual Key Opinion Leader event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum on Dec 9, 2025 at 3:00 PM ET. The session, titled “A Clinician’s Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy”, will feature Dr. Victoria Parikh, Associate Professor of Cardiovascular Medicine at Stanford and Director of the Stanford Center for Inherited Cardiovascular Disease, plus an expert clinician scientist who treats patients with PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). Analysts and investors may register via the company’s News & Events page, and a replay will be archived in Lexeo’s investor section after the event.
Lexeo Therapeutics (NASDAQ:LXEO) reported Q3 2025 results and program updates on Nov 5, 2025. Key clinical and corporate highlights include FDA acceptance to pool Phase I/II LX2006 data with pivotal data for a potential BLA path, and FDA approval in November 2025 of an analytical comparability report endorsing the Sf9 commercial manufacturing process for LX2006. Interim LX2006 data show 18% LVMI improvement at 6 months, 23% at 12 months (n=6 with abnormal baseline), and a 2.0-point mean mFARS improvement (n=16). Lexeo closed a $154 million equity financing in October 2025; Q3 cash was $122.8M (pre-proceeds), and proceeds are expected to fund operations into 2028.
Lexeo Therapeutics (Nasdaq: LXEO) closed an underwritten public offering and a concurrent private placement on Oct 20, 2025, raising approximately $153.8 million in gross proceeds before fees and expenses.
Details: the public offering sold 17,968,750 common shares at $8.00 per share (including full exercise of a 2,343,750-share underwriter option) for gross proceeds of about $143.8 million. The concurrent private placement sold pre-funded warrants to purchase 1,250,015 shares to Balyasny Asset Management for about $10 million. Joint book-runners and placement agents were named and registration materials were filed with the SEC.
Lexeo Therapeutics (Nasdaq: LXEO) priced an underwritten public offering and a concurrent private placement to raise approximately $135 million in gross proceeds before underwriting discounts, commissions and expenses. Lexeo offered 15,625,000 common shares at $8.00 per share and granted a 30‑day option to underwriters to purchase up to 2,343,750 additional shares. Concurrently, Lexeo agreed to sell 1,250,015 pre‑funded warrants to Balyasny Asset Management at $7.9999 per warrant. The transactions are expected to close on or about October 20, 2025, subject to customary closing conditions.